Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma

We have previously shown that disruption of promyelocytic leukemia nuclear bodies (PML NBs) is sufficient to activate the EBV lytic cycle thus making infected cells susceptible to ganciclovir (GCV) mediated killing in vitro. Here we show that co-administration of GCV and arsenic trioxide (ATO), a PM...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sides, Mark D, Sosulski, Meredith L, Luo, Fayong, Lin, Zhen, Flemington, Erik K, Lasky, Joseph A
Format:	Artigo
Language:	Inglês
Published:	BioMed Central 2013
Subjects:	Research
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3666899/ https://ncbi.nlm.nih.gov/pubmed/23680002 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1743-422X-10-152
Tags:	Add Tag No Tags, Be the first to tag this record!

Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma

Similar Items